Organon's VTAMA ® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis
'With 6.6 million adults in the US living with moderate to severe AD, innovative treatment options that meet the highest standards for efficacy, safety, and tolerability are necessary to help provide lasting relief. We are proud of the AAD's strong evidence-based recommendation from the ADORING 1 and ADORING 2 8-week clinical trials for VTAMA cream—a once daily, steroid-free topical with no label restrictions on use based on disease severity, percentage of body surface area affected, or duration of use,' said Juan Camilo Arjona Ferreira, Head of Research and Development and Chief Medical Officer at Organon. 'This strong recommendation, paired with the findings from our Phase 3 ADORING 3 48-week, open-label, long-term extension study which uncovered the possibility of a treatment-free interval lasting on average 80 days after treatment success, highlights how VTAMA cream has the potential to redefine the AD treatment landscape and provide lasting results.'
The focused update incorporates topical and systemic therapies that have been recently approved by the US Food and Drug Administration (FDA) into the AAD's existing guidance on the management of AD in adults to ensure the dermatology community has access to the best available evidence.
In December 2024, the FDA approved VTAMA cream for the topical treatment of AD in adults and pediatric patients 2 years of age and older. VTAMA cream was also approved by the FDA on May 24, 2022, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults.
INDICATIONS: VTAMA ® (tapinarof) cream, 1% is an aryl hydrocarbon receptor (AhR) agonist indicated for:
the topical treatment of plaque psoriasis in adults
the topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older
SELECTED SAFETY INFORMATION
Adverse Events: In plaque psoriasis, the most common adverse reactions (incidence ≥1%) were: folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza.
Adverse Events: In atopic dermatitis, the most common adverse reactions (incidence ≥1%) were: upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma, vomiting, ear infection, pain in extremity, and abdominal pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Before prescribing VTAMA cream, please read the Prescribing Information.
For more information about VTAMA (tapinarof) cream, 1%, visit www.vtamahcp.com.
About Atopic Dermatitis
AD, commonly referred to as eczema, is one of the most prevalent inflammatory skin diseases, affecting over 26 million people in the US alone and up to 10% of adults worldwide. 1,2 AD occurs most frequently in children, affecting up to 20% worldwide. 1,2 The disease results in itchy, red, swollen, and cracked skin, often on the folds of the arms, back of the knees, hands, face, and neck. 3 Itching is an especially bothersome symptom for those with AD, and tends to worsen at night, which can disturb sleep. 1
About Organon
Organon (NYSE: OGN) is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women's Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately, or differently affect women, while expanding access to essential treatments in over 140 markets.
Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare. Learn more at www.organon.com and follow us on LinkedIn, Instagram, X, YouTube, TikTok and Facebook.
Cautionary Note Regarding Forward-Looking Statements
Except for historical information, this press release includes 'forward-looking statements' within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about Organon's expectations about the potential impact of VTAMA as a treatment option for AD. Forward-looking statements may be identified by words such as 'potential,' 'mission,' 'expects,' 'will,' or words of similar meaning. These statements are based upon the current beliefs and expectations of Organon's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Factors that could cause results to differ materially from those described in the forward-looking statements can be found in Organon's filings with the SEC, including Organon's most recent Annual Report on Form 10-K and subsequent SEC filings, available at the SEC's Internet site (www.sec.gov). Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
1 Eczema stats. National Eczema Association. Accessed June 5, 2025.
2 Global Report on Atopic Dermatitis 2022. International League of Dermatological Societies: 2022. Accessed February 25, 2025. https://www.eczemacouncil.org/assets/docs/global-report-on-atopic-dermatitis-2022.pdf
3 What is eczema? National Eczema Association. Accessed July 2, 2025. https://nationaleczema.org/eczema/
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
27 minutes ago
- Miami Herald
Massive sleep study reveals surprising cost of going to bed late
As an avid Oura user, I'm no stranger to *slightly* obsessing over sleep data. I've tracked my deep sleep, REM cycles, HRV, and recovery scores like a mini scientist in a silk sleep mask. I've timed workouts based on my readiness score. When it comes to the link between sleep and performance, I'm not new here. But even with all that tracking and optimization, this new study got my attention. Researchers looked at millions of nights of sleep-over 6 million to be exact-and what they found was something most of us (myself included) tend to overlook. It's not just about how much you sleep. Related: FDA eliminates 52 food standards in sweeping deregulation move It's about when. And more specifically: what happens when you go to bed later than usual. The impact? Subtle at first. But if you're trying to be consistent with your workouts, boost your energy, or just feel better, those late nights might be holding you back. Even if you're still getting 7 to 8 hours of sleep. That's what makes this study different. Because this time, we're not just talking about sleep duration. We're talking about timing-and how it can affect your body and behavior the very next day. The study, published in PNAS, looked at over 6 million nights of sleep data from nearly 26,000 adults using wearable fitness trackers. Specifically, over 19,000 WHOOP users and nearly 6,000 Fitbit device users. Here's what they found: people who went to bed earlier were more likely to exercise the next day. And the difference? Bigger than you'd think. For example, compared to those who went to sleep around 1 a.m., people who consistently went to bed at 9 p.m. logged 28 more minutes of moderate-to-vigorous physical activity (MVPA) the next day. Even more surprising? People who slept less overall, but went to bed earlier, often exercised more than those who slept longer but went to bed later. In other words, timing beat out total sleep when it came to getting people moving. I spoke with Dr. Mark Czeisler, Resident Physician at Brigham and Women's Hospital and Clinical Fellow at Harvard Medical School, who co-authored the study led by Josh Leota, a Research Fellow at Monash University. Related: These clean food brands are rightfully challenging the FDA He explained why bedtime and not just sleep time matters: "People got the most intense exercise when they preserved their usual sleep amount, but went to bed earlier than they typically do," he said. "That suggests these health behaviors aren't competing with each other. They're best thought of as working in concert." Think about it: if you're staying up late to finish one more episode or scroll TikTok, you could be trading away the energy and motivation you'll need tomorrow. Dr. Czeisler also noted that early sleepers are more likely to get in their workouts before the day gets busy. Morning routines tend to be more reliable-and that consistency matters. While this study tracked people living their normal lives-not under lab conditions-it's truly a big moment for sleep and fitness tech. And it supports something companies like WHOOP, Fitbit, Apple Watch and Oura have been saying for years: when you sleep matters just as much as how much you sleep. The WHOOP data came from users who were already pretty active-averaging 90 minutes of MVPA daily. But the researchers confirmed the same trend in a broader group, using Fitbit data from the NIH's All of Us program. Even people who weren't exercising much still saw a difference. Earlier bedtimes meant more movement the next day. As Dr. Czeisler put it: "The way to guarantee exercise is really to protect the morning. And so going to bed earlier, you know, lends itself to doing that." So if you're trying to get consistent with your workouts, improve your energy, or just build better habits, maybe start by looking at the clock. Going to bed a little earlier might be the simplest, most powerful performance tool you're not using yet. Protect your mornings, people! I know I do... Related: Watch out Fitbit and Apple Watch, Amazon has entered the chat The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Business Insider
40 minutes ago
- Business Insider
J.P. Morgan Weighs In on UnitedHealth Stock Amid DOJ Scrutiny
UnitedHealth (NYSE:UNH) stock slipped again on Thursday, a familiar pattern in what's shaping up to be a rough year. Shares have tumbled 44% year-to-date, weighed down by a string of negative developments, including disappointing Q1 results, a CEO change, the suspension of guidance, and rising costs tied to UHC's Medicare Advantage members. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Thursday's 5% drop was driven by renewed scrutiny over an ongoing legal matter. UNH disclosed that it had proactively reached out to the DOJ following a February Wall Street Journal report revealing a civil investigation into its Medicare Advantage risk-coding practices. In its latest filing, the company confirmed that it is now responding to formal civil and criminal inquiries, has launched its own internal review, and remains cooperative with CMS audits. UNH also pointed to a favorable March ruling from a Special Master in a separate, long-running DOJ civil case as a sign of how past challenges have played out. This shift from 'unaware' in February to 'proactively cooperating' now isn't surprising to J.P. Morgan analyst Lisa Gill, who views the company's engagement as part of a broader defense of its practices. 'While we are not lawyers,' Gill noted, 'we note that if the court were to view this case similarly to previous ones brought forth by DOJ regarding the False Claims Act (FCA), we believe that this would place the burden of proof on the DOJ to prove improper coding.' Though the investigation has added another layer of uncertainty, Gill contextualizes it within broader industry trends. The analyst points to risk-adjustment programs like RADV and regulatory updates like V28 as ongoing efforts to refine coding practices across the Medicare Advantage landscape. Viewed through that lens, the current probes may ultimately reflect how companies have adapted, rather than acted improperly. Still, Gill acknowledges the ambiguity facing investors. The company's filing offers limited detail, and any legal proceedings stemming from the DOJ's inquiries are likely to be drawn out. Much could hinge on the outcome of the ongoing DOJ-backed civil case – one in which the Special Master recently recommended dismissal due to lack of evidence, though the DOJ has challenged that recommendation. In the meantime, Gill is looking ahead to next week's earnings call for added clarity, and remains optimistic. The analyst assigns UNH an Overweight (i.e., Buy) rating and $418 price target, suggesting the stock could rebound by 48% over the next 12 months. (To watch Gill's track record, click here) And she's not alone. 17 other analysts share Gill's bullish outlook, while 5 remain on the sidelines and just one is bearish. Altogether, the stock carries a Moderate Buy consensus rating. The average price target stands at $348.12, implying a ~24% upside from current levels. (See UNH stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Yahoo
7 hours ago
- Yahoo
Healthpeak Properties (DOC) Drops 6.7% on Steep Q2 Earnings Dive
We recently published . Healthpeak Properties, Inc. (NYSE:DOC) is one of the worst-performing stocks on Friday. Healthpeak Properties declined by 6.73 percent on Friday to close at $17.6 apiece following a steep drop in its earnings performance in the second quarter of the year. In its earnings release, Healthpeak Properties, Inc. (NYSE:DOC) said net income attributable to shareholders during the period fell by 78 percent to $31.5 million from $145.8 million in the same period last year, dragging its first half figures by 51 percent to $73.9 million from $152 million year-on-year. Revenues for the quarter ended flat at $694 million, while revenues for the first half dropped by 7 percent to $1.397 billion from $1.3 billion year-on-year. Following the performance, Healthpeak Properties, Inc. (NYSE:DOC) lowered its growth guidance for full-year 2025, with diluted earnings per common share now pegged at 25-31 cents from 30-36 cents previously. On July 31, shareholders as of July 18 will receive dividends worth $0.10167 for each common share held. Another dividend with the same amount will be paid on August 29, for shareholders as of the August 18 record. While we acknowledge the potential of DOC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
